Next Article in Journal
The Roles of Protein Tyrosine Phosphatases in Hepatocellular Carcinoma
Next Article in Special Issue
Targeting the Hippo Pathway Is a New Potential Therapeutic Modality for Malignant Mesothelioma
Previous Article in Journal
Aptamer Therapeutics in Cancer: Current and Future
Previous Article in Special Issue
Linking Extracellular Matrix Agrin to the Hippo Pathway in Liver Cancer and Beyond
Article Menu
Issue 3 (March) cover image

Export Article

Open AccessReview

Targeting the Hippo Pathway and Cancer through the TEAD Family of Transcription Factors

Department of Early Discovery Biochemistry, Genentech, Inc., South San Francisco, CA 94080, USA
*
Author to whom correspondence should be addressed.
Cancers 2018, 10(3), 81; https://doi.org/10.3390/cancers10030081
Received: 23 February 2018 / Revised: 15 March 2018 / Accepted: 16 March 2018 / Published: 20 March 2018
  |  
PDF [2589 KB, uploaded 3 May 2018]
  |  

Abstract

The Hippo pathway is a critical transcriptional signaling pathway that regulates cell growth, proliferation and organ development. The transcriptional enhanced associate domain (TEAD) protein family consists of four paralogous transcription factors that function to modulate gene expression in response to the Hippo signaling pathway. Transcriptional activation of these proteins occurs upon binding to the co-activator YAP/TAZ whose entry into the nucleus is regulated by Lats1/2 kinase. In recent years, it has become apparent that the dysregulation and/or overexpression of Hippo pathway effectors is implicated in a wide range of cancers, including prostate, gastric and liver cancer. A large body of work has been dedicated to understanding the therapeutic potential of modulating the phosphorylation and localization of YAP/TAZ. However, YAP/TAZ are considered to be natively unfolded and may be intractable as drug targets. Therefore, TEAD proteins present themselves as an excellent therapeutic target for intervention of the Hippo pathway. This review summarizes the functional role of TEAD proteins in cancer and assesses the therapeutic potential of antagonizing TEAD function in vivo. View Full-Text
Keywords: TEAD; Hippo; YAP; TAZ; cancer; transcription factor TEAD; Hippo; YAP; TAZ; cancer; transcription factor
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Holden, J.K.; Cunningham, C.N. Targeting the Hippo Pathway and Cancer through the TEAD Family of Transcription Factors. Cancers 2018, 10, 81.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top